Trial testing remdesivir plus Olumiant begins enrollment

11 May 2020

A previously-announced trial testing Eli Lilly’s (NYSE: LLY) immunology drug Olumiant (baricitinib) plus remdesivir in COVID-19 has started enrolling in the USA.

More than 1,000 people in hospital with the novel coronavirus will take part in the trial, at around 100 sites around the world. The trial is backed by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

A number of immunologicals have been proposed as possible therapies for severe COVID-19, including Kevzara (sarilumab) from Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), and Actemra (tocilizumab), from Roche (ROG: SIX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK